Table 1 Comparison between patients with low and high AR-Score
From: Androgen deficiency is associated with a better prognosis in glioblastoma
AR-Score | p-value | ||
|---|---|---|---|
Low (n = 13) | High (n = 12) | ||
Age (years) | 64.31 (SD = 14.00) | 66.08 (SD = 7.33) | 0.7441 |
Gender (male:female) | 7:6 | 6:6 | 1.02 |
Karnofsky < 70 | – | 2 (16.7%) | 0.1252 |
Biopsy/partial | |||
Resection | – | 2 (16.7%) | 0.0232 |
Subtotal | 1 (7.7%) | 5 (41.7%) | |
Total | 12 (92.3%) | 5 (41.7%) | |
Ki67 | 22.77 (SD = 17.64) | 31.78 (SD = 20.34) | 0.0761 |
MGMT methylation | 6 (46.2%) | 5 (41.7%) | 1.02 |
Pattern of contrast enhancement | |||
Peripheric | 6 (46.2%) | 6 (50.0%) | 1.02 |
Heterogeneous | 7 (53.8%) | 6 (50.0%) | |
Enhancing tumor (cc) | 18.03 (SD = 15.57) | 22.22 (SD = 10.44) | 0.4241 |
Edema (cc) | 70.39 (SD = 39.92) | 43.13 (SD = 23.30) | 0.1401 |
Necrosis (cc) | 9.38 (SD = 8.65) | 6.66 (SD = 9.66) | 0.3241 |
Necrosis-to-contrast ratio | 0.86 (SD = 0.99) | 0.26 (SD = 0.32) | 0.0741 |
AR expression (WB) (Z-value) | -0.30 (SD = 1.01) | -0.49 (SD = 0.84) | 0.1881 |
ARn/t fluorescence | 0.15 (SD = 0.05) | 0.19 (SD = 0.07) | 0.2781 |
Androgen deficiency (n = 21) | 5 (45.5%) | 6 (60.0%) | 0.6702 |
Progression-free survival (days) | 194.0 [0–449.5] | 172.0 [143.3–200.6] | 0.4273 |
Men | 637.0 [73.7–1200.3] | 168.0 [84.0–252.0] | 0.0163 |
Women | 103.0 [86.2–119.8] | 186.0 [17.0–355.0] | 0.4693 |
Overall survival (days) | 687.0 [246.7–1127.3] | 406.0 [274.4–537.6] | 0.2583 |
Men | 864.0 [209.7–1518.3] | 301.0 [211.7–390.3] | 0.0393 |
Women | 474.0a [193.8–754.5] | 420.0a [263.2–576.2] | 0.9643 |